Allergy Therapeutics (LON:AGY) Releases Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) posted its quarterly earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%.

Allergy Therapeutics Stock Performance

Shares of Allergy Therapeutics stock opened at GBX 5.70 ($0.07) on Wednesday. Allergy Therapeutics has a 52 week low of GBX 2.65 ($0.03) and a 52 week high of GBX 8 ($0.10). The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The stock has a market capitalization of £280.16 million, a price-to-earnings ratio of -5.49, a PEG ratio of -30.70 and a beta of 1.40. The firm has a fifty day moving average of GBX 6.57 and a two-hundred day moving average of GBX 5.92.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.